Clinical Trials Arena on MSN
Neurocrine Biosciences begins phase II NBI-1065890 trial for TD
The double-blind, placebo-controlled Phase II trial is enrolling approximately 100 adult participants with tardive dyskinesia ...
THE National Bureau of Investigation in Central Visayas (NBI) 7 has a new leader at the helm. Jose Ermie Monsanto was ...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with tardive dyskinesia (TD). NBI-1065890 is ...
National Bank Investments Inc. (‟NBI") announced today the January 2026 cash distribution amounts per unit for certain NBI Exchange-Traded Funds (‟NBI ETFs") and ETF Series of NBI Funds (‟NBI ETF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results